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Cognitive impairment is a central feature of schizophre-
nia. Most patients have a poor functional outcome,
including deficits in social, occupational, and self-care
activities. The cost borne by the society in terms of social
welfare administration and criminal justice, the time
spent by unpaid caregivers, and the great loss of produc-
tivity due to the illness itself, are perhaps greater than the
direct costs, such as, hospitalization. Functional deficits in
schizophrenia are most strongly predicted by the current
severity of cognitive impairment, followed by the severity
of negative symptoms. Severity of positive symptoms is
not strongly associated with the level of functional
impairments, even in those with very poor outcome schiz-
ophrenia. There is thus an urgent need to find strategies
for improving cognitive functioning in schizophrenia.
Functional MRI (fMRI) is a non-invasive technique with
good temporal and spatial resolution. It requires no radi-
oactivity and offers the ability to map, almost in real-time,
the physiological events occurring in the brain. fMRI can
be used as a tool to map the longitudinal effects of antip-
sychotic drugs on the brain in schizophrenia. It allows us
to carry out repeated measurements of cerebral neuronal
activity and to investigate functional changes in the brain
in treatment responders and non responders. It is thus
possible to map the functional anatomy of neurocogni-
tive improvement with atypical antipsychotics in schizo-
phrenia. This presentation will outline new methods of
brain imaging and how these methods may allow us to
understand the long-term effects of cognitive improve-
ment with antipsychotic drugs in schizophrenia.
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